Volumetric Muscle Loss (VML) is a specific type of muscle injury characterized by the significant loss of muscle tissue volume, typically resulting from severe trauma, surgical intervention, or other traumatic events. Unlike typical muscle injuries, VML involves the removal or destruction of a substantial amount of muscle mass, impairing the affected muscle's structure and function. In VML, the body's natural regenerative mechanisms struggle to repair the extensive muscle loss, leading to functional deficits and chronic impairment. The condition often occurs in conjunction with damage to blood vessels and nerves within the muscle, further complicating the recovery process. Rehabilitation strategies for VML focus on stimulating muscle regeneration and preventing fibrotic tissue formation. Researchers explore various approaches, including stem cell therapy, tissue engineering, and regenerative medicine, to enhance muscle regeneration and functional recovery in individuals with VML. The long-term consequences of VML can be profound, impacting not only muscle strength and mobility but also contributing to secondary issues such as joint instability and altered biomechanics. Managing VML requires a multidisciplinary approach involving physical therapy, surgical interventions, and innovative regenerative therapies to address the complex challenges associated with significant muscle loss.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Will be updated soon...
Vasiliki E Kalodimou, European University-Cyprus Ltd, Cyprus
Title : Will be updated soon...
Nagy Habib, Imperial College London, United Kingdom
Title : Will be updated soon...
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : Advanced 3D tissue models: Pioneering tools for investigating health and disease
Lucie Bacakova, Institute of Physiology of the Czech Academy of Sciences, Czech Republic
Title : Developing iPSC-derived 3D Outer Blood-Retinal Barrier Disease Models of Choroideremia for Gene Therapy Evaluation
Aradhana Kasimsetty, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), United States